Immatics

$11.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-0.45%) As of 5:46 PM UTC today

Why Robinhood?

You can buy or sell Immatics and other stocks, options, and ETFs commission-free!

About IMTX

Immatics N.V. Ordinary Shares, also called Immatics, is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCERâ„¢). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany. The listed name for IMTX is Immatics N.V. Ordinary Shares.

CEO
Harpreet Singh-Jasuja
Employees
227
Headquarters
Tuebingen, Baden Wuerttemberg
Founded
2020
Market Cap
715.89M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
201.19K
High Today
$11.40
Low Today
$10.93
Open Price
$11.28
Volume
38.22K
52 Week High
$17.25
52 Week Low
$8.67

IMTX Earnings

-$0.45
-$0.30
-$0.15
-$0.00
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 12, Pre-Market

You May Also Like

CRTDW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure